Profound Medical (PROF)
(Delayed Data from NSDQ)
$7.69 USD
+0.21 (2.81%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $7.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.69 USD
+0.21 (2.81%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $7.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Zacks News
Profound Medical (PROF) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 0% and 10.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 33.33% and 9.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -45.22% and 7.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -7.58% and 4.66%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Profound Medical (PROF) Adds AI to Prostate Cancer Treatment
by Zacks Equity Research
Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.
ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
electroCore (ECOR) delivered earnings and revenue surprises of -6% and 5.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer
by Zacks Equity Research
Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -33.90% and 20.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How Much Upside is Left in Profound Medical (PROF)? Wall Street Analysts Think 66.06%
by Zacks Equity Research
The mean of analysts' price targets for Profound Medical (PROF) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of -12.90% and 21.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
What Makes Profound Medical (PROF) a New Buy Stock
by Zacks Equity Research
Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -18.18% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Moves 9.4% Higher: Will This Strength Last?
by Zacks Equity Research
Profound Medical (PROF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
After Plunging -15.27% in 4 Weeks, Here's Why the Trend Might Reverse for Profound Medical (PROF)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Profound Medical (PROF) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zoetis (ZTS) Matches Q4 Earnings Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Recent Price Trend in Profound Medical (PROF) is Your Friend, Here's Why
by Zacks Equity Research
Profound Medical (PROF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 29.41% and 15.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Profound Medical (PROF) Q2 Earnings Expected to Decline
by Zacks Equity Research
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.